NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS
Serbia
Stats

Importance

RS Family Size
|
Non-US Coverage
|
Abstract
The compound of the following formula, wherein R1 and R2 are selected from the following table: R1 R2 EstarAla OPh cPentAla OCH2CF3 EtAla OPh 3-furan-4HAla OPh cButPhe (B) OPh EtPhe (A) OPh EtAla (B) OPh EtPhe OPh sBu ) Phe OPh cBuPhe OCH2CF3 iBuAla (A) OPh EtPhe OPh sBu (R) Ala (B) OPh CH2cPrAla (A) OPh CH2cPrPhe (B) OPh nBuPhe (A) OPh nBuPhe OPh CH2cPrPhe OPh CH2cBuAla OPh 3-pentABA (B) OPh eTab (A) OPh Etal OPh CH2cBuMet OPh ETR1 R2 EstarPro OPh BnPhe (B) OPh iBuPhe (A) OPh iBuPhe OPh iPrPhe OPh NPRA OPh CH2cPrPhe OPh Etal OPh eTab OPh nPentPhe Phe nPrPhe Phe Etal Ala etch OPh MeGly OPh iPrABA OPh nBuPhe OPh AliiAla OPh nPentGly OPh iBuABA OPh iBuAla OPh nBuCHA CHA MePhe Phe AliiABA ABA nPentGly Gly iBuGly Gly iPrPhe OPh iBuAla OPh nPrPhe OPh nBuABA OPh nPrABA OPh Etal Ala Bn R1 R2 EstarPhe OPh nBuABA ABA nPrABA ABA Etal Ala NPRA OPh IPRA OPh BnAla Ala nBuAla Ala iBuABA ABA nBuABA ABA iPrAla OPh iBuABA OPh MeABA OPh iPrABA ABA iBugde Ala represents L-alanine, Phe represents L-phenylalanine n, Met represents L-methionine, ABA represents (S) -2-aminobutyric acid, Pro represents L-proline, CHA represents 2-amino-3- (S) cyclohexyl-propionic acid, Gly represents glycine; R1 or R2 are amino acid carboxylic the groups are esterified as indicated in the ester column, gdecPent is a cyclopent ester; Et is ethyl ester, 3-furan-4H is (R) tetrahydrofuran-3-yl ester; cBut is a cyclobutane ester; sBu (S) is (S) secButyl ester; sBu (R) is (R) secButyl ester; iBu isobutyl ester; CH2cPr is methylcyclopropane ester, nBu is n-butyl ester; CH2cBu is a methylcyclobutane ester; 3-pent is 3-pentyl ester; nPent is nPentyl ester; iPr is isopropyl ester, nPr is nPropyl ester; allyl is an allyl ester; Me is methyl ester; Bn is a benzyl ester; wherever A or B in parentheses denote one stereoisomer on phosphorus, where the less polar isomer is designated as (A) and the polar isomer as (B), or a pharmacologically acceptable salt or solvate thereof. The application contains 11 more claims.

First Claim
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Country Designations

Patent Owner(s)
- Owner owned or assignment not recorded
International Classification(s)
Inventor(s)
- No Inventor to display
Cited Art Landscape
- No Cited Art to Display

Full Text

Legal Events

Matter Detail

Renewals Detail

Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:

Add to additional portfolios:

Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement

Recipient Email Address

Recipient Email Address

Comment
Recipient Email Address

Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
Important Notes on Latency of Status data
This Status indicator is an estimation based on the relevant document kind code. As such, it status will only indicate "Published" or "Granted". Expired, lapsed or abandoned statuses are not available in this release. Please refer to the legal status information for more information.
This status should not be taken as legal conclusion. No representations are made as to the accuracy of the status provided. Please consult a legal professional before relying on this status information.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
Only for Granted EP cases
EP validations represent the countries in which the EP patent may be in force. Data is based on reporting from the various EP contracting states. The reporting consistency can vary across the countries.